Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 290

Results For "MANA"

2996 News Found

AYUSH 64 effective in mild and moderate COVID 19
Drug Approval | August 03, 2021

AYUSH 64 effective in mild and moderate COVID 19

It works as an adjunct to standard care based on robust clinical trials


Ajanta Pharma aims to file 10-12 ANDAs per annum
News | August 02, 2021

Ajanta Pharma aims to file 10-12 ANDAs per annum

India business is growing as per projections; whereas US business will bounce back soon.


Granules India earmarks Rs 400 crore as Capex for FY 22
News | August 02, 2021

Granules India earmarks Rs 400 crore as Capex for FY 22

The company has an outlay of Rs 120-140 crore as R & D expense for FY 22


Bharat Biotech gets WHO prequalification for ROTAVAC 5D
Biotech | August 02, 2021

Bharat Biotech gets WHO prequalification for ROTAVAC 5D

WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO


Windlas Biotech opens for subscription this week
Biotech | August 02, 2021

Windlas Biotech opens for subscription this week

Proceeds from the IPO will be used for the expansion of the Dehradun facility.


RPG Life Sciences Q1FY22 PAT surges to Rs. 13.58 Cr
News | July 29, 2021

RPG Life Sciences Q1FY22 PAT surges to Rs. 13.58 Cr

The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.


Granules India Q1FY22 consolidated net profit at Rs. 120.20 Cr
News | July 28, 2021

Granules India Q1FY22 consolidated net profit at Rs. 120.20 Cr

The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.


Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr
News | July 28, 2021

Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr

The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.


Hugely successful vaccination roll out made possible by India-UK partnership
Policy | July 28, 2021

Hugely successful vaccination roll out made possible by India-UK partnership

The contribution of Wockhardt at Wrexham is one of the best examples of the success and significant potential of India-UK partnerships in the healthcare sector


Morepen to start Sputnik V Vaccine commercial production in 4-6 weeks
News | July 28, 2021

Morepen to start Sputnik V Vaccine commercial production in 4-6 weeks

The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval